Agnese Fabbri

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

Gianluca Masi, E. Vasile, Fotios Loupakis et al. · JNCI Journal of the National Cancer Institute · 2010 · 188 citations

<i>KRAS</i> mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy

Mirko Marabese, Monica Ganzinelli, Marina Chiara Garassino et al. · Oncotarget · 2015 · 87 citations · Full text

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Giulia Bon, Laura Pizzuti, Valentina Laquintana et al. · Journal of Experimental & Clinical Cancer Research · 2020 · 72 citations · Full text

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

Patrizia Vici, Laura Pizzuti, Andrea Michelotti et al. · Oncotarget · 2017 · 68 citations · Full text